MITSUBISHI-ENG-PLASTICS
1.6.2021 03:02:05 CEST | Business Wire | Press release
Mitsubishi Engineering-Plastics Corporation (MEP), a world leader in high-performance polyacetal materials, has developed a new polyacetal resin (POM), the Iupital MA Series, that is compliant with medical standards.
The MA series is available in a range of standard, high-flow, high-rigidity, and low-friction grades, enabling greater design flexibility for medical devices and equipment, which are becoming smaller and lighter.
In particular, the low-friction grade MAL20 has greatly improved sliding performance with POM. In the past, combining POM parts would generate squeaking noise and friction, so designs would combine different materials in order to avoid these issues. MAL20 suppresses friction and wear, even when combined with ordinary POM, achieving quiet, smooth movement, which greatly improves comfort when used in medical devices.
In addition, with the MA series, we will offer a coloring masterbatch for color mixing. We support parts design not only in terms of physical characteristics, but also in terms of visual design.
MEP Vice President, Katsushige Hayashi, said the following. "These new materials, which exhibit a variety of excellent properties, will expand the range of designs, especially for medical devices and instruments, and contribute to improving their functionality. In particular, the sliding grade MAL20 eliminates the discomfort caused by noise and friction due to contact between POMs, providing users with comfort and ease of use."
The Iupital MA series meets the quality and regulatory requirements for medical materials, and is suitable for applications such as drug inhalers for COPD and asthma, injection devices such as insulin pens, and parts for medical devices.
Overview of Mitsubishi Engineering-Plastics Corporation
- Headquarters: Minato-ku, Tokyo
- Branches: Osaka Branch (Osaka, Osaka Prefecture), Nagoya Branch (Nagoya, Aichi Prefecture)
- Technical Base: Technical Center (Hiratsuka, Kanagawa Prefecture)
- President: Takashi Komaya
- Capital: 3 billion yen (50% invested by each of Mitsubishi Gas Chemical Company, Inc. and Mitsubishi Chemical Corporation)
Basic Information on the Iupital ™ MA Series
Features
- We offer a variety of grade groups in addition to the standard grades, including high flow, high rigidity, and low friction
- Masterbatch coloring available
- Worldwide sales and technical support
Grade Lineup
- MAS20 Standard: This is the grade with the most common physical properties and flowability
- MAS30 High flow: This grade has increased flowability. Suitable for precision molding
- MAH25 High rigidity: This grade has increased rigidity and strength. Suitable for making thinner walls and increasing strength
- MAL20 Low-friction: This grade has excellent sliding characteristics. It contributes to low-noise designs with low sliding resistance
Supported Standards, Etc.
- ISO10993-5, 10
- USP [87]
- USP [88] Class IV
- FDA Drug Master File
For data on physical properties, etc., please download it from our website, or contact our sales staff at the nearest head office, branch office, or local subsidiary.
Basic Physical Properties Charts
https://www.m-ep.co.jp/ja/eve/18-2.html (Japanese)
https://www.m-ep.co.jp/en/eve/18-2.html (English)
https://www.m-ep.co.jp/ch/eve/18-2.html (Chinese)
Sales Bases
https://www.m-ep.co.jp/company/kaigai.html (Japanese)
https://www.m-ep.co.jp/en/company/kaigai.html (English)
https://www.m-ep.co.jp/ch/company/kaigai.html (Chinese)
View source version on businesswire.com: https://www.businesswire.com/news/home/20210531005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom